Drugs / ER-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07290244 | Mar 2026 → May 2027 expected | non-arteritic anterior ischemic optic neuropathy, open-angle glaucoma | Life Biosciences Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-01-28 | Life Biosciences Inc. | Regulatory Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies lifebiosciences.com ↗ |
| 2025-08-26 | Life Biosciences Inc. | Results Life Biosciences Presents New Data at ARDD 2025 on the Company’s Partial Epigenetic Reprogramming Platform in Liver and Ocular Diseases lifebiosciences.com ↗ |
| 2024-10-21 | Life Biosciences Inc. | Results Life Biosciences Presents at AAO Highlighting Progress of Nonhuman Primate Studies Evaluating Partial Epigenetic Reprogramming to Restore Visual Function lifebiosciences.com ↗
Furthermore, ER-100 significantly reduced deficits in pattern electroretinogram and axon density measures when administered in both prevention and rescue paradigms. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Life Biosciences Inc. | Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026 lifebiosciences.com ↗ |
| 2026-01-28 | Life Biosciences Inc. | Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies lifebiosciences.com ↗ |
| 2025-08-26 | Life Biosciences Inc. | Life Biosciences Presents New Data at ARDD 2025 on the Company’s Partial Epigenetic Reprogramming Platform in Liver and Ocular Diseases lifebiosciences.com ↗ |
| 2024-10-21 | Life Biosciences Inc. | Life Biosciences Presents at AAO Highlighting Progress of Nonhuman Primate Studies Evaluating Partial Epigenetic Reprogramming to Restore Visual Function lifebiosciences.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ER-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07290244 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “modified adeno-associated virus (AAV) vector” NCT07290244 ↗ |
| Route | Intravitreal | “administered via intravitreal injection” NCT07290244 ↗ |